A new research has revealed that anti-psychotic drugs could help treat some major cancers.
According to a preliminary finding in the current online issue of the International Journal of Cancer, the anti-psychotic drug, pimozide, kills lung, breast and brain cancer cells in in-vitro laboratory experiments.
In the new study, pimozide was the most lethal of six anti-psychotic drugs tested by a team from UNSW and the University of Queensland. Rapidly-dividing cancer cells require cholesterol and lipids to grow and the researchers suspect that pimozide kills cancer cells by blocking the synthesis or movement of cholesterol and lipid in cancer cells.
To test the idea that pimozide acts by disrupting cholesterol homeostasis, the researchers combined pimozide with mevastatin, a drug that inhibits cholesterol production in cells. The two drugs were more lethal in combination against cancer cells than when either drug was used alone.
"The combination of pimozide and mevastatin increased cancer cell death," says UNSW researcher Dr Louise Lutze-Mann, a co-author of the study.
"We needed a lower dose of each drug to kill the same amount of cells," the expert added.
Although side-effects are associated with the use of high doses of these drugs - such as tremors, muscle spasms and slurred speech - these effects are considered to be tolerable in patients where other treatments have failed and the drugs will only be used short-term. These side-effects would be reduced if the drugs were used in combination with a lipid-lowering drug, such as mevastatin.
The researchers have also investigated the effects of olazapine , a "second-generation" antipsychotic drug, and found that it also kills cancer cells but has a better side-effect profile.
When administered to patients, it accumulates in the lung, which suggests that it may prove to be most useful in treating lung cancer.